Effects of a potent peroxynitrite decomposition catalyst in murine models of endotoxemia and sepsis

Shock

Volumn 35, Issue 6, 2011, Pages 560-566

  Soriano, Francisco Garcia ^a   Lorigados, Clara Batista ^a   Pacher, Pal ^b   Szabó, Csaba ^c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[FE(III)TETRAKIS 2 (N TRIETHYLENE GLYCOL MONOMETHYL ETHER)PYRIDYL PORPHYRIN]; ALANINE AMINOTRANSFERASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MALONALDEHYDE; MYELOPEROXIDASE; NITRATE; NITRITE; PEROXYNITRITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOTOXEMIA; INTESTINE INJURY; KIDNEY INJURY; LIVER INJURY; LUNG INJURY; MOUSE; NONHUMAN; SEPSIS; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ENDOTOXEMIA; LIPOPOLYSACCHARIDES; MALONDIALDEHYDE; METALLOPORPHYRINS; MICE; NITRATES; NITRITES; PEROXIDASE; PEROXYNITROUS ACID; SEPSIS;

EID: 79957888168     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31820fe5d5     Document Type: Article

References (44)

1. Winters BD, Eberlein M, Leung J, Needham DM, Pronovost PJ, Sevransky JE: Long-term mortality and quality of life in sepsis: a systematic review. Crit Care Med 38:1276-1283, 2010.
2. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546-1554, 2003. (Pubitemid 36437931)
3. Texereau J, Pene F, Chiche JD, Rousseau C, Mira JP: Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit Care Med 32(Suppl 5):S313-S319, 2004.
4. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D: Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reper-fusion injury. Pharmacol Rev 53:135-159, 2001. (Pubitemid 32173112)
5. Wittebole X, Castanares-Zapatero D, Laterre PF: Toll-like receptor 4 modulation as a strategy to treat sepsis. Mediators Inflamm 2010:568396, 2010.
6. Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA: Phylogenetic perspectives in innate immunity. Science 284:1313-1318, 1999. (Pubitemid 29289650)
7. Freeman BD, Natanson C: Anti-inflammatory therapies in sepsis and septic shock. Expert Opin Investig Drugs 9:1651-1663, 2000. (Pubitemid 30433723)
8. Vincent JL, Sun Q, Dubois MJ: Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 34:1084-1093, 2001.
9. Ulloa L, Brunner M, Ramos L, Deitch EA: Scientific and clinical challenges in sepsis. Curr Pharm Des 15:1918-1935, 2009.
10. Marshall JC, Dellinger RP, Levy M: The Surviving Sepsis Campaign: a history and a perspective. Surg Infect (Larchmt) 11:275-281, 2010.
11. Szabo C, Ischiropoulos H, Radi R: Peroxynitrite: biochemistry, pathophysiol-ogy and development of therapeutics. Nat Rev Drug Discov 6:662-680, 2007. (Pubitemid 47207751)
12. Pacher P, Beckman JS, Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87:315-424, 2007. (Pubitemid 46217686)
13. Szabo C, Salzman AL, Ischiropoulos H: Peroxynitrite-mediated oxidation of dihydrorhodamine 123 occurs in early stages of endotoxic and hemorrhagic shock and ischemia-reperfusion injury. FEBS Lett 372:229-232, 1995.
14. Lange M, Connelly R, Traber DL, Hamahata A, Nakano Y, Esechie A, Jonkam C, von Borzyskowski S, Traber LD, Schmalstieg FC, et al.: Time course of nitric oxide synthases, nitrosative stress, and poly(ADP ribosylation) in an ovine sepsis model. Crit Care 14:R129, 2010.
15. Soriano FG, Nogueira AC, Caldini EG, Lins MH, Teixeira AC, Cappi SB, Lotufo PA, Bernik MM, Zsengellér Z, Chen M, et al.: Potential role of poly(adenosine 5¶-diphosphate-ribose) polymerase activation in the patho-genesis of myocardial contractile dysfunction associated with human septic shock. Crit Care Med 34:1073-1079, 2006.
16. Pacher P, Szabo C: Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. Am J Pathol 173:2-13, 2008. (Pubitemid 351947950)
17. Szabó C, Mabley JG, Moeller SM, Shimanovich R, Pacher P, Virag L, Soriano FG, Van Duzer JH, Williams W, Salzman AL, et al.: Pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med 8:571-580, 2001. (Pubitemid 36337502)
18. Szabó C, Módis K: Pathophysiological roles of peroxynitrite in circulatory shock. Shock 34(Suppl 1):4-14, 2010.
19. Jagtap P, Soriano FG, Virág L, Liaudet L, Mabley J, Szabó E, Haskó G, Marton A, Lorigados CB, Gallyas F Jr, et al.: Novel phenanthridinone inhibitors of poly (adenosine 5¶-diphosphate-ribose) synthetase: potent cytoprotective and anti-shock agents. Crit Care Med 30:1071-1082, 2002. (Pubitemid 34508031)
20. Soriano FG, Liaudet L, Szabó E, Virág L, Mabley JG, Pacher P, Szabó C: Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1Ydeficient mice. Shock 17:286-292, 2002.
21. Jagtap P, Szabó C: Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4:421-440, 2005. (Pubitemid 40704125)
22. Tanaka K, Ishihara T, Azuma A, Kudoh S, Ebina M, Nukiwa T, Sugiyama Y, Tasaka Y, Namba T, Ishihara T, et al.: Therapeutic effect of lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 298:L348-L360, 2010.
23. McCord JM: Superoxide dismutase, lipid peroxidation, and bell-shaped dose response curves. Dose Response 6:223-238, 2008.
24. Ishihara T, Tanaka K, Tasaka Y, Namba T, Suzuki J, Ishihara T, Okamoto S, Hibi T, Takenaga M, Igarashi R, et al.: Therapeutic effect of lecithinized super-oxide dismutase against colitis. J Pharmacol Exp Ther 328:152-164, 2009.
25. Nelson SK, Bose SK, McCord JM: The toxicity of high-dose superoxide dis-mutase suggests that superoxide can both initiate and terminate lipid perox-idation in the reperfused heart. Free Radic Biol Med 16:195-200, 1994. (Pubitemid 24117500)
26. Galiñanes M, Ferrari R, Qiu Y, Cargnoni A, Ezrin A, Hearse DJ: PEG-SOD and myocardial antioxidant status during ischaemia and reperfusion: dose-response studies in the isolated blood perfused rabbit heart. J Mol Cell Cardiol 24:1021-1030, 1992.
27. Omar BA, McCord JM: The cardioprotective effect of Mn-superoxide dis-mutase is lost at high doses in the postischemic isolated rabbit heart. Free Radic Biol Med 9:473-478, 1990. (Pubitemid 120036907)
28. Lefer AM, Lefer DJ: Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock. Annu Rev Pharmacol Toxicol 33:71-90, 1993. (Pubitemid 23116001)
29. Levrand S, Pesse B, Feihl F, Waeber B, Pacher P, Rolli J, Schaller MD, Liaudet L: Peroxynitrite is a potent inhibitor of NF-.B activation triggered by inflammatory stimuli in cardiac and endothelial cell lines. J Biol Chem 280:34878-34887, 2005. (Pubitemid 41504622)
30. Loukili N, Rosenblatt-Velin N, Rolli J, Levrand S, Feihl F, Waeber B, Pacher P, Liaudet L: Oxidants positively or negatively regulate nuclear factor kappaB in a context-dependent manner. J Biol Chem 285:15746-15752, 2010.
31. Zacharowski K, Olbrich A, Cuzzocrea S, Foster SJ, Thiemermann C: Membrane-permeable radical scavenger, tempol, reduces multiple organ injury in a rodent model of gram-positive shock. Crit Care Med 28:953-961, 2000.
32. Chatterjee PK, Cuzzocrea S, Brown PA, Zacharowski K, Stewart KN, Mota-Filipe H, Thiemermann C: Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat. Kidney Int 58:658-673, 2000. (Pubitemid 30620015)
33. Salvemini D, Riley DP, Lennon PJ, Wang ZQ, Currie MG, Macarthur H, Misko TP: Protective effects of a superoxide dismutase mimetic and peroxynitrite decomposition catalysts in endotoxin-induced intestinal damage. Br J Pharmacol 127:685-692, 1999. (Pubitemid 29276654)
34. Cuzzocrea S, Mazzon E, Di Paola R, Esposito E, Macarthur H, Matuschak GM, Salvemini D: A role for nitric oxideYmediated peroxynitrite formation in a model of endotoxin-induced shock. J Pharmacol Exp Ther 319:73-81, 2006. (Pubitemid 44455112)
35. Naidu BV, Fraga C, Salzman AL, Szabo C, Verrier ED, Mulligan MS: Critical role of reactive nitrogen species in lung ischemia-reperfusion injury. J Heart Lung Transplant 22:784-793, 2003. (Pubitemid 36842931)
36. Maybauer DM, Maybauer MO, Szabó C, Westphal M, Traber LD, Enkhbaatar P, Murthy KG, Nakano Y, Salzman AL, Herndon DN, et al.: Lung-protective effects of the metalloporphyrinic peroxynitrite decomposition catalyst WW-85 in interleukin-2 induced toxicity. Biochem Biophys Res Commun 377:786-791, 2008.
37. Maybauer DM, Maybauer MO, Szabó C, Cox RA, Westphal M, Kiss L, Horvath EM, Traber LD, Hawkins HK, Salzman AL, et al.: The peroxyni-trite catalyst WW-85 improves pulmonary function in ovine septic shock [published online ahead of print]. Shock 35:148-155, 2011.
38. Mabley JG, Liaudet L, Pacher P, Southan GJ, Groves JT, Salzman AL, Szabó C: Beneficial effects of the peroxynitrite decomposition catalyst FP15 in murine models of arthritis and colitis. Mol Med 8:581-590, 2002. (Pubitemid 36337503)
39. Genovese T, Mazzon E, Esposito E, Di Paola R, Murthy K, Neville L, Bramanti P, Cuzzocrea S: Effects of a metalloporphyrinic peroxynitrite decomposition catalyst, WW-85, in a mouse model of spinal cord injury. Free Radic Res 43:631-645, 2009.
40. Bianchi C, Wakiyama H, Faro R, Khan T, McCully JD, Levitsky S, Szabó C, Sellke FW: A novel peroxynitrite decomposer catalyst (FP-15) reduces myo-cardial infarct size in an in vivo peroxynitrite decomposer and acute ischemia-reperfusion in pigs. Ann Thorac Surg 74:1201-1207, 2002. (Pubitemid 35176747)
41. Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM, Virág L, Deb A, Szabó E, Ungvári Z, Wolin MS, et al.: Potent metalloporphyrin peroxyni-trite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 107:896-904, 2003. (Pubitemid 36241050)
42. Tauskela JS, Brunette E, Hewitt M, Mealing G, Morley P: Competing approaches to excitotoxic neuroprotection by inert and catalytic antioxidant porphyrins. Neurosci Lett 401:236-241, 2006. (Pubitemid 43729525)
43. Obrosova IG, Drel VR, Oltman CL, Mashtalir N, Tibrewala J, Groves JT, Yorek MA: Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats. Am J Physiol Endocrinol Metab 293:E1645-E1655, 2007. (Pubitemid 350255115)
44. Radovits T, Seres L, Gero D, Lin LN, Beller CJ, Chen SH, Zotkina J, Berger I, Groves JT, Szabó C, et al.: The peroxynitrite decomposition catalyst FP15 improves ageing-associated cardiac and vascular dysfunction. Mech Ageing Dev 128:173-181, 2007. (Pubitemid 46109011)